Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women

Table 2 Comparison of the result of the treatment of Asian patients with untreated characterised KRAS exon 2 wt MCC between groups at the final follow-up

Variable	CAP-B (n = 130)	CAP (n = 133)	P-value
Deaths	64	85	0.016*^a
Recurrence	7	18	0.024*^a
Metastatic brain/leptomeningeal tumours	11	18	0.189^a
> 3 metastases^b	13	24	0.061^a

^*Statistically significant values. ^aAnalysed using the chi-square test. ^bincluding the brain, bone, lung, liver, and lymph nodes. CAP-B capecitabine plus bevacizumab, CAP capecitabine, MCC metastatic colorectal cancer

ISSN: 1471-230X